TargetMol

YQA14

Product Code:
 
TAR-T29195
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T29195-5mg5mg£850.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T29195-50mg50mg£1,661.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T29195-100mg100mg£2,079.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
YQA14 is a selective antagonist of D3 receptor.
CAS:
1221408-42-9
Formula:
C23H27ClN4O3
Molecular Weight:
442.94
Purity:
0.98
SMILES:
Cc1ccc(Cl)cc1N1CCN(CCCCNC(=O)c2ccc3oc(=O)[nH]c3c2)CC1

References

1. Sun L, Song R, Chen Y, Yang RF, Wu N, Su RB, Li J. A selective D3 receptor antagonist YQA14 attenuates methamphetamine-induced behavioral sensitization and conditioned place preference in mice. Acta Pharmacol Sin. 2016 Feb;37(2):157-65. doi: 10.1038/aps.2015.96. Epub 2015 Dec 21. PubMed PMID: 26687935; PubMed Central PMCID: PMC4753378. 2. Liu F, Wang X, Li Z, Li J, Zhuang X, Zhang Z. P-Glycoprotein (ABCB1) limits the brain distribution of YQA-14, a novel dopamine D3 receptor antagonist. Chem Pharm Bull (Tokyo). 2015;63(7):512-8. doi: 10.1248/cpb.c15-00089. PubMed PMID: 26133067. 3. Chen Y, Song R, Yang RF, Wu N, Li J. A novel dopamine D3 receptor antagonist YQA14 inhibits methamphetamine self-administration and relapse to drug-seeking behaviour in rats. Eur J Pharmacol. 2014 Nov 15;743:126-32. doi: 10.1016/j.ejphar.2014.09.026. Epub 2014 Sep 26. PubMed PMID: 25261038. 4. Liu F, Zhuang X, Yang C, Li Z, Xiong S, Zhang Z, Li J, Lu C, Zhang Z. Characterization of preclinical in vitro and in vivo ADME properties and prediction of human PK using a physiologically based pharmacokinetic model for YQA-14, a new dopamine D3 receptor antagonist candidate for treatment of drug addiction. Biopharm Drug Dispos. 2014 Jul;35(5):296-307. doi: 10.1002/bdd.1897. Epub 2014 Apr 13. PubMed PMID: 24647883.